vs

Side-by-side financial comparison of BGC Group, Inc. (BGC) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

BGC Group, Inc. is the larger business by last-quarter revenue ($638.6M vs $321.1M, roughly 2.0× MADRIGAL PHARMACEUTICALS, INC.). BGC Group, Inc. runs the higher net margin — 2.3% vs -18.2%, a 20.5% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 34.4%). BGC Group, Inc. produced more free cash flow last quarter ($175.1M vs $-133.8M).

BGC Group, Inc. is an American global financial services company based in New York City and London. Originally formed as part of the larger Cantor Fitzgerald organization, BGC Partners became its own entity in 2004.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

BGC vs MDGL — Head-to-Head

Bigger by revenue
BGC
BGC
2.0× larger
BGC
$638.6M
$321.1M
MDGL
Growing faster (revenue YoY)
MDGL
MDGL
+176.4% gap
MDGL
210.8%
34.4%
BGC
Higher net margin
BGC
BGC
20.5% more per $
BGC
2.3%
-18.2%
MDGL
More free cash flow
BGC
BGC
$309.0M more FCF
BGC
$175.1M
$-133.8M
MDGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BGC
BGC
MDGL
MDGL
Revenue
$638.6M
$321.1M
Net Profit
$14.4M
$-58.6M
Gross Margin
Operating Margin
3.9%
-18.6%
Net Margin
2.3%
-18.2%
Revenue YoY
34.4%
210.8%
Net Profit YoY
-43.0%
1.4%
EPS (diluted)
$0.03
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BGC
BGC
MDGL
MDGL
Q4 25
$638.6M
$321.1M
Q3 25
$620.8M
$287.3M
Q2 25
$648.0M
$212.8M
Q1 25
$534.6M
$137.3M
Q4 24
$475.2M
$103.3M
Q3 24
$448.9M
$62.2M
Q2 24
$435.0M
Q1 24
$453.6M
$0
Net Profit
BGC
BGC
MDGL
MDGL
Q4 25
$14.4M
$-58.6M
Q3 25
$27.9M
$-114.2M
Q2 25
$57.5M
$-42.3M
Q1 25
$55.2M
$-73.2M
Q4 24
$25.2M
$-59.4M
Q3 24
$14.7M
$-107.0M
Q2 24
$37.8M
Q1 24
$49.2M
$-147.5M
Gross Margin
BGC
BGC
MDGL
MDGL
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
BGC
BGC
MDGL
MDGL
Q4 25
3.9%
-18.6%
Q3 25
5.4%
-39.7%
Q2 25
11.6%
-22.2%
Q1 25
15.0%
-57.8%
Q4 24
5.7%
-64.8%
Q3 24
4.4%
-187.1%
Q2 24
12.7%
Q1 24
15.7%
Net Margin
BGC
BGC
MDGL
MDGL
Q4 25
2.3%
-18.2%
Q3 25
4.5%
-39.8%
Q2 25
8.9%
-19.9%
Q1 25
10.3%
-53.4%
Q4 24
5.3%
-57.5%
Q3 24
3.3%
-172.0%
Q2 24
8.7%
Q1 24
10.8%
EPS (diluted)
BGC
BGC
MDGL
MDGL
Q4 25
$0.03
$-2.55
Q3 25
$0.06
$-5.08
Q2 25
$0.11
$-1.90
Q1 25
$0.11
$-3.32
Q4 24
$0.04
$-2.50
Q3 24
$0.03
$-4.92
Q2 24
$0.08
Q1 24
$0.10
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BGC
BGC
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$851.5M
$198.7M
Total DebtLower is stronger
$1.5B
$339.9M
Stockholders' EquityBook value
$972.5M
$602.7M
Total Assets
$4.4B
$1.3B
Debt / EquityLower = less leverage
1.58×
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BGC
BGC
MDGL
MDGL
Q4 25
$851.5M
$198.7M
Q3 25
$774.9M
$295.7M
Q2 25
$827.8M
$186.2M
Q1 25
$966.4M
$183.6M
Q4 24
$711.6M
$100.0M
Q3 24
$563.5M
$232.7M
Q2 24
$571.7M
Q1 24
$566.8M
$622.5M
Total Debt
BGC
BGC
MDGL
MDGL
Q4 25
$1.5B
$339.9M
Q3 25
$1.8B
$339.8M
Q2 25
$1.8B
$118.4M
Q1 25
$1.1B
$118.0M
Q4 24
$1.1B
$117.6M
Q3 24
$1.4B
$117.1M
Q2 24
$1.4B
Q1 24
$945.0M
$116.1M
Stockholders' Equity
BGC
BGC
MDGL
MDGL
Q4 25
$972.5M
$602.7M
Q3 25
$965.3M
$625.7M
Q2 25
$930.5M
$696.0M
Q1 25
$963.8M
$710.6M
Q4 24
$898.5M
$754.4M
Q3 24
$860.1M
$777.2M
Q2 24
$858.1M
Q1 24
$912.1M
$850.8M
Total Assets
BGC
BGC
MDGL
MDGL
Q4 25
$4.4B
$1.3B
Q3 25
$5.8B
$1.4B
Q2 25
$4.9B
$1.0B
Q1 25
$4.9B
$996.6M
Q4 24
$3.6B
$1.0B
Q3 24
$4.4B
$1.1B
Q2 24
$4.3B
Q1 24
$4.4B
$1.1B
Debt / Equity
BGC
BGC
MDGL
MDGL
Q4 25
1.58×
0.56×
Q3 25
1.90×
0.54×
Q2 25
1.97×
0.17×
Q1 25
1.19×
0.17×
Q4 24
1.27×
0.16×
Q3 24
1.68×
0.15×
Q2 24
1.68×
Q1 24
1.04×
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BGC
BGC
MDGL
MDGL
Operating Cash FlowLast quarter
$180.4M
$-133.5M
Free Cash FlowOCF − Capex
$175.1M
$-133.8M
FCF MarginFCF / Revenue
27.4%
-41.7%
Capex IntensityCapex / Revenue
0.8%
0.1%
Cash ConversionOCF / Net Profit
12.55×
TTM Free Cash FlowTrailing 4 quarters
$372.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BGC
BGC
MDGL
MDGL
Q4 25
$180.4M
$-133.5M
Q3 25
$141.9M
$79.8M
Q2 25
$71.2M
$-47.1M
Q1 25
$839.0K
$-88.9M
Q4 24
$251.9M
$-104.5M
Q3 24
$88.3M
$-67.0M
Q2 24
$-53.0M
Q1 24
$28.1M
$-149.2M
Free Cash Flow
BGC
BGC
MDGL
MDGL
Q4 25
$175.1M
$-133.8M
Q3 25
$137.2M
$79.0M
Q2 25
$65.0M
Q1 25
$-4.4M
Q4 24
$245.6M
$-104.7M
Q3 24
$78.8M
$-67.8M
Q2 24
$-63.5M
Q1 24
$24.9M
$-149.5M
FCF Margin
BGC
BGC
MDGL
MDGL
Q4 25
27.4%
-41.7%
Q3 25
22.1%
27.5%
Q2 25
10.0%
Q1 25
-0.8%
Q4 24
51.7%
-101.3%
Q3 24
17.5%
-109.0%
Q2 24
-14.6%
Q1 24
5.5%
Capex Intensity
BGC
BGC
MDGL
MDGL
Q4 25
0.8%
0.1%
Q3 25
0.8%
0.3%
Q2 25
1.0%
0.0%
Q1 25
1.0%
0.0%
Q4 24
1.3%
0.2%
Q3 24
2.1%
1.3%
Q2 24
2.4%
Q1 24
0.7%
Cash Conversion
BGC
BGC
MDGL
MDGL
Q4 25
12.55×
Q3 25
5.09×
Q2 25
1.24×
Q1 25
0.02×
Q4 24
9.99×
Q3 24
5.99×
Q2 24
-1.40×
Q1 24
0.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BGC
BGC

Commissions$590.2M92%
Data Software And Post Trade$36.7M6%
Fees From Related Parties$4.6M1%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons